Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of pediatric rheumatism and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116. The company was founded in 2010 and is headquartered in Umeå, Sweden.
Target Price
The average target price of LIPUM.ST is 16 and suggests 11% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio